We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
The U.S. Court of Appeals for the Federal Circuit recently affirmed a district court’s denial of a request by Altana Pharma and Wyeth (collectively Altana) for a preliminary injunction to prevent Teva Pharmaceuticals (Teva) from marketing a generic version of the anti-ulcer drug Protonix
